Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
94.2M
-
Number of holders
-
219
-
Total 13F shares, excl. options
-
108M
-
Shares change
-
+3.14M
-
Total reported value, excl. options
-
$4.49B
-
Value change
-
+$150M
-
Put/Call ratio
-
0.2
-
Number of buys
-
120
-
Number of sells
-
-107
-
Price
-
$41.65
Significant Holders of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) as of Q3 2025
263 filings reported holding CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock as of Q3 2025.
Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) has 219 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 108M shares
.
Largest 10 shareholders include FMR LLC (14.2M shares), VANGUARD GROUP INC (9.17M shares), WELLINGTON MANAGEMENT GROUP LLP (8.38M shares), BlackRock, Inc. (7.59M shares), Driehaus Capital Management LLC (6.48M shares), FARALLON CAPITAL MANAGEMENT LLC (5.77M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.31M shares), EcoR1 Capital, LLC (4.29M shares), JANUS HENDERSON GROUP PLC (3.86M shares), and Paradigm Biocapital Advisors LP (2.55M shares).
This table shows the top 219 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.